ERBB2 and breast cancer: Trastuzumab (Herceptin) is a FDA-approved recombinant humanized monoclonal antibody developed against the extracellular domain of the HER2 protein, which is currently used as a therapy for HER2-overexpressing breast cancer patients [11–14].